Salvesen
Carlo Salvesen, Munich DE
Patent application number | Description | Published |
---|---|---|
20090200463 | Charged Particle Beam Device With Retarding Field Analyzer - The invention provides a charged particle beam device to inspect or structure a specimen with a primary charged particle beam propagating along an optical axis; a beam tube element having a tube voltage; and a retarding field analyzer in the vicinity of the beam tube element to detect secondary charged particles generated by the primary charged particle beam on the specimen. According to the invention, the retarding field analyzer thereby comprises an entrance grid electrode at a second voltage; at least one filter grid electrode at a first voltage; a charged particle detector to detect the secondary charged particles; and at least one further electrode element arranged between the entrance grid electrode and the at least one filter grid electrode. The at least one further electrode element reduces the size of the stray fields regions in the retarding electric field region to improve the energy resolution of the retarding field analyzer. The improvement of the energy resolution is significant, in particular when the beam tube element is part of a high voltage beam tube. | 08-13-2009 |
Carlo Salvesen, Massing DE
Patent application number | Description | Published |
---|---|---|
20090026384 | ELECTROSTATIC LENS ASSEMBLY - A lens assembly having an electrostatic lens component for a charged particle beam system is provided. The assembly includes: a first electrode having a conically shaped portion, a second electrode having a conically shaped portion, and a first insulator having a conically shaped portion, wherein the first insulator comprises two extending portions towards each of its ends, and wherein the two extending portions are formed to generate a gap between the insulator and each of the adjacent electrodes. | 01-29-2009 |
20090039280 | MAGNETIC LENS ASSEMBLY - A lens assembly having a magnetic lens assembly for a charged particle beam system is provided. The lens assembly includes: a first pole piece having a connecting portion of the first pole piece and a gap portion of the first pole piece, a second pole piece having a connecting portion of the second pole piece and a gap portion of the second pole piece, wherein the first pole piece and the second pole piece provide a gap at the respective gap portions, a coil for exciting the magnetic lens assembly, a centering element comprising a material that has a smaller Young's modulus than the material of the first and the material of the second pole piece, wherein the pole pieces are connected with each other at the respective connecting portions and have a centering element receiving portion towards the respective gap portion ends of the pole pieces. | 02-12-2009 |
20130306863 | ELEMENT FOR FAST MAGNETIC BEAM DEFLECTION - A deflector system for fast magnetic deflection of a charged particle beam is described. The deflector system includes a tube for separating the beam from the magnetic deflector coil arrangement, the tube having a middle section, at least a first end section, and a second end section, wherein a wall thickness of the middle section is lower than a wall thickness of at least one of the first end section and the second end section. | 11-21-2013 |
Clifford Randall Salvesen, Ostrander, OH US
Patent application number | Description | Published |
---|---|---|
20110017535 | AUTOMOBILE OVER-BULKHEAD AIR INTAKE SYSTEM - A vehicle air intake system includes a grille disposed along the front portion of an engine compartment, a hood disposed over the engine compartment and a bulkhead cover disposed in the engine compartment below the hood. The bulkhead cover has a bulkhead cover intake port and a deflector disposed along and extending forwardly from a lower portion of the bulkhead cover intake port to circuitously redirect airflow passing from the grille to the bulkhead cover intake port. | 01-27-2011 |
Guy Salvesen, Encinitas, CA US
Patent application number | Description | Published |
---|---|---|
20140024597 | INTRANASAL DELIVERY OF CELL PERMEANT THERAPEUTICS - The present invention relates to compositions and methods for the inhibition of apoptosis associated with ischemic injury in the central nervous system. In addition, the present invention relates to compositions and methods useful for extending the therapeutic window associated with ischemic injury. | 01-23-2014 |
Guy S. Salvesen, Encinitas, CA US
Patent application number | Description | Published |
---|---|---|
20110059465 | SCREENING ASSAYS FOR AGENTS THAT ALTER INHIBITOR OF APOPTOSIS (IAP) PROTEIN REGULATION OF CASPASE ACTIVITY - The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP. In addition, the invention provides methods of modulating the ability of a population of cells to survive ex vivo by contacting the cells with an agent that alters the caspase inhibitory activity of an IAP in the cells. | 03-10-2011 |
20120094922 | SCREENING ASSAYS FOR AGENTS THAT ALTER INHIBITOR OF APOPTOSIS (IAP) PROTEIN REGULATION OF CASPASE ACTIVITY - The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7 or a pro-caspase such as pro-caspase-9, or that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP. | 04-19-2012 |
Helga B. Salvesen, Paradis NO
Patent application number | Description | Published |
---|---|---|
20110217701 | Prognostic Marker for Endometrial Carcinoma - The present invention relates to a method for diagnosis of different stages of endometrial cancer in an individual. Further, the present invention relates to a method for evaluating the probability of survival for an individual suffering from endometrial carcinoma. In another aspect, the present invention relates to the stratification of therapy regimen of endometrial tumor, ovarian cancer, breast cancer, non-small lung cancer or hormone refractory prostate cancer therapy in an individual or monitoring therapeutic efficacy in an individual suffering from the same based on the expression status of STMN1 gene or protein. Moreover, the present invention relates to a kit for use in any of the above referenced methods comprising a means for determining amplifications and deletions of chromosomal regions 3q26.32 and 12p12.1, determining alterations of the gene expression profile of the genes (gene signature): upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes: NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein, respectively. Finally, the present invention provides a method for predicting the response to taxanes in an individual suffering from a disease treated with the taxanes based on the expression status of the STMN1 gene or protein. | 09-08-2011 |
20130267440 | MARKER FOR CARCINOMA - The present invention relates to a method for diagnosis of different stages of endometrial cancer in an individual. Further, the present invention relates to a method for evaluating the probability of survival for an individual suffering from endometrial carcinoma. In another aspect, the present invention relates to the stratification of therapy regimen of endometrial tumor, ovarian cancer, breast cancer, non-small lung cancer or hormone refractory prostate cancer therapy in an individual or monitoring therapeutic efficacy in an individual suffering from the same based on the expression status of STMN1 gene or protein. Moreover, the present invention relates to a kit for use in any of the above referenced methods comprising a means for determining amplifications and deletions of chromosomal regions 3q26.32 and 12p12.1, determining alterations of the gene expression profile of the genes (gene signature): upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes: NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein, respectively. Finally, the present invention provides a method for predicting the response to taxanes in an individual suffering from a disease treated with the taxanes based on the expression status of the STMN1 gene or protein. | 10-10-2013 |
20130338026 | Prognostic Marker for Endometrial Carcinoma - A method for diagnosis of different stages of endometrial cancer and for evaluating the probability of survival for an individual suffering from endometrial carcinoma, and for stratification of a therapy regimen for an endometrial tumor or monitoring therapeutic efficacy in an individual suffering considers the expression status of STMN1 gene or protein. A kit for use in the methods allows for determining amplifications and deletions of chromosomal regions 3q26.32 and 12p12.1, determining alterations of the gene expression profile of the genes (gene signature): upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes: NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein. | 12-19-2013 |
20140200155 | Prognostic marker for endometrial carcinoma - The present invention relates to a method for diagnosing or determining the status of endometrial carcinoma in an individual afflicted with or suspected to be afflicted with endometrial carcinoma based on the phosphorylated stathmin compound whereby said stathmin is phosphorylated at position Serine 38. Moreover, the present invention relates to a method for evaluating the probability of survival, the clinical outcome or the treatment course of an individual afflicted with or suspected to be afflicted with endometrial carcinoma. In another aspect, the present invention relates to the stratification of the therapeutic regimen of an individual with endometrial carcinoma. In particular, the present invention provides a method for diagnosing or identifying endomentrial carcinoma with high grade aggressive phenotype, in particular, having low response and susceptibility to chemotherapeutic regimen, in particular, with respect to microtubule stabilization based regimen including treatment with taxanes. Moreover, the present invention relates to a kit for use in any of the above-referenced methods comprising means for determining the level or amount of phosphorylated pStathmin(S38) as well as assays for conducting the method according to the present invention. In one embodiment, the methods according to the present invention include the combined determination of stathmin and phosphorylated stathmin (pStathmin(S38)). | 07-17-2014 |
Helge Rune Salvesen, Bjorbekk NO
Patent application number | Description | Published |
---|---|---|
20100046730 | SUBSCRIBER BARRING OF TELEMARKETING - A system is disclosed for barring unwanted calls comprising at least a calling party, a protocol, a receiving party where the calling party is connected to an originating node, and the receiving party is connected to a terminating node. The system further comprises means adapted to provide the calling party with at least one category/identifier, means adapted to give the receiving party a possibility to access a service/application on the terminating node where the receiving party can indicate at least one user defined category, and a protocol having spare bits suitable for transportation of the calling party's at least one category/identifier. It is further disclosed a corresponding method for barring unwanted calls. | 02-25-2010 |
Richard S. Salvesen, Hampton, IA US
Patent application number | Description | Published |
---|---|---|
20110193438 | PULSE ADAPTER ASSEMBLY - A pulse adapter assembly that includes a pulse assembly that has a housing with a cavity disposed therein that receives a sensing device and a driven magnet. The adapter assembly has a shaft having a bearing assembly thereon and driver magnet wherein the shaft is disposed within the cavity of the pulse assembly such that the driven magnet and driver magnet couple to position the driven magnet at a predetermined distance from the sensing device. A workpiece such as a flow meter is attached to the adapter assembly wherein the sensing device monitors the driven magnet to determine an operational parameter of the workpiece. | 08-11-2011 |
Robert H. Salvesen, Sandwich, IL US
Patent application number | Description | Published |
---|---|---|
20090215557 | Institutional badminton racket - An institutional badminton racket including a head and a flexible plastic handle. The head has a metal rim around a shuttlecock striking face, and a neck rigidly secured to the rim, where the neck includes a hollow throat extending from the rim away from the striking face with lateral openings through the throat. The handle connecting end includes a first portion extending into the hollow throat, a second portion surrounding the throat, pin portions extending through the throat lateral openings and integral with the first and second portions, and a pair of wings extending generally in the plane in a lateral direction toward the head and including openings therethrough. A Y-clamp is secured around the handle connecting end and the head rim adjacent the head neck and including pins extending through the wing openings. | 08-27-2009 |
Rudi Salvesen, Kabelvag NO
Patent application number | Description | Published |
---|---|---|
20150159336 | Container for collecting pollution - It is disclosed a container for collecting pollution floating on water, comprising an upper wall ( | 06-11-2015 |
Tormod Salvesen, Sor-Audnedal NO
Patent application number | Description | Published |
---|---|---|
20080232967 | Centrifugal Fan - The invention relates to an impeller device ( | 09-25-2008 |
William R. Salvesen, Brooklyn, NY US
Patent application number | Description | Published |
---|---|---|
20120144970 | Delivering Foil Leaves of Selected Lengths from an Indeterminate Length of Foil - A method and apparatus deliver consecutive foil leaves for use by a hair stylist during the course of a hair styling procedure. Each leaf is of a selected length severed from a supply of foil of indeterminate length, with a unitary tab folded along a fold line extending across the leaf, adjacent a leading edge of the leaf. The foil preferably is drawn from a roll of foil and is advanced along a feed path to a delivery station, and a cutter and folder are moved across the feed path to sever the leaf from the indeterminate length of foil and establish the tab adjacent the leading edge of the leaf. In the preferred arrangement, the cutter and the folder are moved simultaneously along respective arcuate paths by pivotal movement about a common pivotal axis. | 06-14-2012 |